SUPERNUS PHARMACEUTICALS INC

SUPERNUS PHARMACEUTICALS INC Share · US8684591089 · SUPN · A1JX3U (XNMS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of SUPERNUS PHARMACEUTICALS INC
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
9
5
0
0
No Price
01.05.2026 20:37
Current Prices from SUPERNUS PHARMACEUTICALS INC
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
SUPN
USD
01.05.2026 20:37
47,85 USD
-0,15 USD
-0,31 %
IEXG: IEX
IEX
SUPN
USD
01.05.2026 19:59
47,85 USD
-0,15 USD
-0,31 %
XLON: London
London
0LB2.L
USD
01.05.2026 13:34
47,32 USD
-0,68 USD
-1,42 %
XDUS: Düsseldorf
Düsseldorf
SPIRSD89.DUSB
EUR
30.04.2026 06:10
41,00 EUR
-
XDQU: Quotrix
Quotrix
SPIRSD89.DUSD
EUR
30.04.2026 05:27
41,40 EUR
-
Share Float & Liquidity
Free Float 94,56 %
Shares Float 54,45 M
Shares Outstanding 57,58 M
Invested Funds

The following funds have invested in SUPERNUS PHARMACEUTICALS INC:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
49,89
Percentage (%)
0,12 %
Company Profile for SUPERNUS PHARMACEUTICALS INC Share
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Company Data

Name SUPERNUS PHARMACEUTICALS INC
Company Supernus Pharmaceuticals, Inc.
Symbol SUPN
Website https://www.supernus.com
Primary Exchange XNMS NASDAQ/NMS (GLOBAL MARKET)
WKN A1JX3U
ISIN US8684591089
Asset Class Share
Sector Healthcare
Industry Medical - Pharmaceuticals
CEO Jack A. Khattar
Market Capitalization 3 Mrd.
Country United States of America
Currency USD
Employees 0,7 T
Address 9715 Key West Avenue, 20850 Rockville
IPO Date 2018-01-29
Dividends from 'SUPERNUS PHARMACEUTICALS INC'
Ex-Date Dividend per Share
15.03.2022 0,29 USD

Ticker Symbols

Name Symbol
Düsseldorf SPIRSD89.DUSB
Frankfurt S49.F
London 0LB2.L
NASDAQ SUPN
Quotrix SPIRSD89.DUSD
More Shares
Investors who hold SUPERNUS PHARMACEUTICALS INC also have the following shares in their portfolio:
AM.FDS-AF EUR.EQ. AEOC
AM.FDS-AF EUR.EQ. AEOC Fund
AMAZON.CO INC
AMAZON.CO INC Share
AMGEN INC
AMGEN INC Share
AUTODESK INC
AUTODESK INC Share
Boston Sand & Gravel Co.
Boston Sand & Gravel Co. Share
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Share
CZANT TECHNOLOGIESLOGY SOLUTIONSCORP - CLASS A
CZANT TECHNOLOGIESLOGY SOLUTIONSCORP - CLASS A Share
GILEAD SCIENCES INC
GILEAD SCIENCES INC Share
INTEL CORP
INTEL CORP Share
MICROSOFT CORP
MICROSOFT CORP Share
UBS(L)EQ.-CN O.DL P-ACC
UBS(L)EQ.-CN O.DL P-ACC Fund
UMA
UMA Crypto
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Share